BioSpace News Archive

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.

Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of Olivia C. Ware and Katrin Rupalla, Ph.D., to its Board of Directors.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Pure Biologics to accelerate the discovery of immuno-oncology antibody-based drugs.

Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication

On April 7, 2021 Oncology Pharma, Inc. reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments utilizing Regens proprietary intellectual property pertaining to mRNA.

Unaudited Financial Results Include Revenue Growth of 133% for Biotricity, Inc.

The Infusion Nurses Society has included the international Aseptic Non Touch Technique framework as a dedicated standard in its recently published 2021 Infusion Therapy Standards of Practice.

Italian Team Led by Dr. Gabriele Messina To Share Novel Operating Room Research Using the UVDI-360 Room Sanitizer at SHEA 2021

Open-label, non-randomized, controlled study will span one year and evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at root cause of type 2 diabetes Study to evaluate the durability of treatment effect and total cost of care impact of BT-001 in a diverse, real-world clinical setting with topline primary endpoint data expected in 2H 2022

Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today two presentations highlighting clinical and preclinical data from the Company’s phenylketonuria (PKU) and MPS II (Hunter syndrome) in vivo gene therapy programs, respectively, at the virtual American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.